Literature DB >> 19346388

Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006.

David M Mutonga1, Guillermo Pimentel, Judith Muindi, Charles Nzioka, Julius Mutiso, John D Klena, Myriam Morcos, Thomas Ogaro, Sadiki Materu, Christopher Tetteh, Nancy E Messonnier, Robert F Breiman, Daniel R Feikin.   

Abstract

The epidemiology of serogroup X meningococcal meningitis in Africa is unknown. During a serogroup X meningococcus outbreak in Kenya, case finding involved record review at health facilities and interviews with health workers and community leaders in West Pokot district. An age- and location-matched case-control study for risk factors was done. From December 2005 to April 2006, 82 suspect cases of meningitis were reported; the epidemic threshold was surpassed within two administrative divisions. Most (58%) cases were 5-24 years old; the case-fatality ratio was 21%. Serogroup X meningococcus was the most common serogroup - 5 (63%) of eight isolates serogrouped. Living in the same compound as another case, preceding upper respiratory tract infection and cooking outside the house were significant risk factors for disease. Serogroup X meningococcus caused an outbreak with similar epidemiology and risk factors as other serogroups. Serogroup-specific laboratory-based surveillance for meningococcus in Africa to detect serogroup X disease should be enhanced.

Entities:  

Mesh:

Year:  2009        PMID: 19346388

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  14 in total

Review 1.  Epidemiological profile of meningococcal disease in the United States.

Authors:  Lee H Harrison
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

Review 2.  Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Authors:  Jamie D Croxtall; Sohita Dhillon
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

3.  Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.

Authors:  Elizabeth E Moran; Robert Burden; Joseph E Labrie; Zhiyun Wen; Xin-Min Wang; Wendell D Zollinger; Lan Zhang; Valerian B Pinto
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

Review 4.  Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.

Authors:  Mustapha M Mustapha; Lee H Harrison
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

5.  Neisseria meningitidis serogroup X sequence type 2888, Italy.

Authors:  Cecilia Fazio; Stefania Starnino; Marina Dal Solda; Tonino Sofia; Arianna Neri; Paola Mastrantonio; Paola Stefanelli
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

6.  Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.

Authors:  Francesca Micoli; Maria Rosaria Romano; Marta Tontini; Emilia Cappelletti; Massimiliano Gavini; Daniela Proietti; Simona Rondini; Erwin Swennen; Laura Santini; Sara Filippini; Cristiana Balocchi; Roberto Adamo; Gerd Pluschke; Gunnstein Norheim; Andrew Pollard; Allan Saul; Rino Rappuoli; Calman A MacLennan; Francesco Berti; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

7.  Epidemiology, molecular characterization and antibiotic resistance of Neisseria meningitidis from patients ≤15 years in Manhiça, rural Mozambique.

Authors:  Ana Belén Ibarz-Pavón; Luis Morais; Betuel Sigaúque; Inacio Mandomando; Quique Bassat; Ariel Nhacolo; Llorenç Quintó; Montse Soriano-Gabarró; Pedro L Alonso; Anna Roca
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

8.  Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

Authors:  Jacqueline M Miller; Narcisa Mesaros; Marie Van Der Wielen; Yaela Baine
Journal:  Adv Prev Med       Date:  2011-07-18

9.  The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.

Authors:  Valerian B Pinto; Robert Burden; Allyn Wagner; Elizabeth E Moran; Che-Hung Lee
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  Nodding syndrome.

Authors:  Scott F Dowell; James J Sejvar; Lul Riek; Katelijn A H Vandemaele; Margaret Lamunu; Annette C Kuesel; Erich Schmutzhard; William Matuja; Sudhir Bunga; Jennifer Foltz; Thomas B Nutman; Andrea S Winkler; Anthony K Mbonye
Journal:  Emerg Infect Dis       Date:  2013       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.